Showing 5251-5260 of 5621 results for "".
- Roche Further Extends Tender Offer for Spark Therapeutics as FTC Review Continueshttps://modernod.com/news/roche-further-extends-tender-offer-for-spark-therapeutics-as-ftc-review-continues/2476508/Roche said Friday that it is extending its offer period related to the proposed acquisition of Spark Therapeutics for a second time to give the US Federal Trade Commission (FTC) more time to review the deal, according to FirstWord. Roche noted that the FTC’s “review of the transaction
- Implandata Gains CE Mark for its Eyemate System for Keratoprosthesishttps://modernod.com/news/implandata-gains-ce-mark-for-its-eyemate-system-for-keratoprosthesis/2476510/Ophthalmic sensors and digital health company Implandata Ophthalmic Products announced that it attained CE mark for its Eyemate system for use in patients undergoing keratoprosthesis surgery. Keratoprosthesis represents an infrequent yet important procedure for restoring vision. It is performed o
- ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Studyhttps://modernod.com/news/reneuron-announces-presentation-of-updated-efficacy-and-safety-data-from-retinitis-pigmentosa-study/2476502/ReNeuron Group announced updated positive preliminary results in the company’s ongoing phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2a part of the trial have demonstr
- Zeiss Launches First Dual-Speed Swept-Source OCT/OCTA at ARVOhttps://modernod.com/news/zeiss-launches-first-dual-speed-swept-source-oct-octa-at-arvo/2476503/Zeiss launched the PLEX Elite 2.0, the first dual-speed swept-source OCT/OCTA that will scan at 200kHz, in addition to 100kHz, providing doctors a more detailed view into the retina. Varying speeds can be applied to different disease states in the eye and expand re
- Presbia Abandons Flexivue Microlens, Lays Off All But 3https://modernod.com/news/presbia-abandons-flexivue-microlens-lays-off-all-but-3/2476501/Presbia said it spiked its Flexivue microlens development program in the face of FDA headwinds, laying off all but three of its employees as it seeks investors to bail it out, according to a Mass Device report. Earlier this month, the Irvine, Calif.-based company
- Ziemer USA Sponsors NIIOS USA Cornea Eveninghttps://modernod.com/news/ziemer-usa-sponsors-niios-usa-cornea-evening-2/2476495/Ziemer USA is sponsoring the Netherlands Institute for Innovative Ocular Surgery (NIIOS) Cornea Evening in San Diego, California, on Friday, May 3, 2019, from 6-11 pm. For the third year in a row, NIIOS USA is organizing a Cornea Evening preceding the Annual Meeting of the American Society
- Study: Microglia Play a Vital Role in Regulating Neuroinflammation in Autoimmune Diseasehttps://modernod.com/news/study-microglia-play-a-vital-role-in-regulating-neuroinflammation-in-autoimmune-disease/2476491/A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the central nervous system—including the retina of the eye—serve as “gatekeepers,” or biosensors and facilitators, of neuroinflammation in a preclinical model of autoimmune uveitis. Uveitis is one o
- First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosahttps://modernod.com/news/first-clinical-program-initiated-using-nanoparticles-to-treat-retinitis-pigmentosa/2476490/2Ctech announced the initiation of the first-known clinical program to demonstrate the effectiveness and safety of Quantum Dots (QDs) to achieve photovoltaic stimulation of the neural retina for preservation or enhancement of vision in patients with retinal degenerative diseases and, in particula
- Optos Wins 2019 Queen’s Award for Enterprise Innovationhttps://modernod.com/news/optos-wins-2019-queens-award-for-enterprise-innovation/2476489/UK-based Optos has been recognized for its innovation with a 2019 Queen’s Award for Enterprise. Optos, which has sold more than 16,000 of its ultra-widefield imaging devices to eyecare professionals across the world, won the coveted accolade for the design of its
- Ivantis Announces Publication of Comparative MIGS Clinical Trial Resultshttps://modernod.com/news/ivantis-announces-publication-of-comparative-migs-clinical-trial-results/2476486/Ivantis, developer of the Hydrus Microstent, announced that the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS) were accepted into the journal Ophthalmology, according to a company news release. COMPARE is the first prospective, multicenter, ra